A 5-Question Quiz on Multiple Myeloma

Article

Are you up to date on the known risk factors for multiple myeloma? How about the latest findings presented at this year’s ASCO meeting?

 

Question 1:

Answer and Question 2 on Next Page »

The correct answer is A. 30,330

 

Question 2:

Answer and Question 3 on Next Page »

The correct answer is D. High-dose melphalan plus autologous stem cell transplantation

 

Question 3:

Answer and Question 4 on Next Page »

The correct answer is C. Workplace exposures

 

Question 4:

Answer and Question 5 on Next Page »

The correct answer is C. 12,650

 

Question 5:

Answer on Next Page »

The correct answer is B. Dexamethasone

Related Videos
A panel of 4 experts on multiple myeloma
A panel of 4 experts on lung cancer
A panel of 4 experts on multiple myeloma
A panel of 4 experts on lung cancer
Video 8 - "Closing Thoughts on the Future of NSCLC"
Video 7 - "Molecular Testing: Key Takeaways on Next Generation Sequencing in NSCLC "
Samer A. Al'Hadidi, MD, with Rahul Gosain, MD, and Rohit Gosain, MD
Samer A. Al'Hadidi, MD, with Rahul Gosain, MD, and Rohit Gosain, MD
Samer A. Al'Hadidi, MD, with Rahul Gosain, MD, and Rohit Gosain, MD
Samer A. Al'Hadidi, MD, with Rahul Gosain, MD, and Rohit Gosain, MD
Related Content
52 UK Experience of Non-Radioisotope, Non-Magnetic Guided Breast Wide Local Excision and Sentinel Node Biopsy

52 UK Experience of Non-Radioisotope, Non-Magnetic Guided Breast Wide Local Excision and Sentinel Node Biopsy

May 17th 2024
Article
Gregory Charak, MD, discusses how modalities like laparoscopic surgery and neoadjuvant immunotherapy may benefit patients with colorectal cancer.

Leveraging Surgical Oncology Advances in Colorectal Cancer Care

May 13th 2024
Podcast

Gregory Charak, MD, discusses how modalities like laparoscopic surgery and neoadjuvant immunotherapy may benefit patients with colorectal cancer.

Data from the phase 1/2 ALKOVE-1 trial support the breakthrough therapy designation for NVL-655 in advanced ALK-positive non–small cell lung cancer.

NVL-655 Receives FDA Breakthrough Therapy Designation in ALK+ NSCLC

May 17th 2024
Article

Data from the phase 1/2 ALKOVE-1 trial support the breakthrough therapy designation for NVL-655 in advanced ALK-positive non–small cell lung cancer.

Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.

Administering CAR T-Cell Therapy and Bispecific Agents in Nursing Practice

May 6th 2024
Podcast

Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.

The phase 2 DELLphi-301 trial showed durable response rates when tarlatamab was used to treat extensive-stage small cell lung cancer.

FDA Approves Tarlatamab After Progression on Chemotherapy in ES-SCLC

May 16th 2024
Article

The phase 2 DELLphi-301 trial showed durable response rates when tarlatamab was used to treat extensive-stage small cell lung cancer.

53 The Utility of Sentinel Lymph Node Biopsy in High-Grade Ductal Carcinoma In Situ

53 The Utility of Sentinel Lymph Node Biopsy in High-Grade Ductal Carcinoma In Situ

May 16th 2024
Article